Corcept Therapeutics FDA CRL Prompts Three-Year Delay Model, Analysts Target $100–$105
Corcept Therapeutics received an FDA Complete Response Letter for relacorilant’s NDA, prompting analysts to model a three-year market entry delay but maintain buy opinions with price targets of $100 and $105, implying 161% to 174% upside. Phase 3 ROSELLA data boosted ovarian cancer market penetration forecasts from 20% to 25%.
1. FDA CRL and Delay Forecast
On February 2, Corcept Therapeutics received a Complete Response Letter from the FDA for relacorilant’s NDA, confirming the need for an additional trial and leading analysts to factor in a three-year market entry delay into their financial models.
2. Analyst Price Target Revisions
Edward Nash of Canaccord Genuity reaffirmed a Buy rating and set a $100 price target (161% upside), while Swayampakula Ramakanth at H.C. Wainwright raised his target from $90 to $105 (174% upside), reflecting confidence in relacorilant’s long-term value despite regulatory setbacks.
3. Phase 3 ROSELLA Data Impact
Based on new median survival results from the Phase 3 ROSELLA study, analysts increased relacorilant’s ovarian cancer market penetration estimate from 20% to 25%, boosting revenue forecasts for this indication and supporting their bullish outlook.